Alvotech (ALVO) Common Equity (2020 - 2026)
Alvotech (ALVO) posted Common Equity of -$282.3 million for Q1 2026, up 0.76% on a QoQ basis from -$284.5 million in Q4 2025, and up 31.61% year-over-year from -$214.5 million in Q1 2025.
Alvotech (ALVO) Common Equity (2020 - 2026) Analysis & Trends
Alvotech's Common Equity history runs 7 years deep, the most recent figure standing at -$282.3 million for Q1 2026.
- Quarterly Common Equity rose 31.61% year-over-year to -$282.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$282.3 million (up 31.61% YoY) and the FY2025 annual result came in at -$284.5 million, up 31.08% from the prior year.
- Common Equity was -$282.3 million for Q1 2026 at Alvotech, up from -$284.5 million in the prior quarter.
- Across five years, Common Equity topped out at -$173.3 million in Q2 2025 and bottomed at -$932.5 million in Q4 2023.
- A 5-year average of -$465.3 million and a median of -$412.8 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 316.2% — and 2025, when it surged 71.39%.
- Alvotech's Common Equity stood at -$564.4 million in 2022, then sank by 65.21% to -$932.5 million in 2023, then soared by 55.73% to -$412.8 million in 2024, then surged by 31.08% to -$284.5 million in 2025, then grew by 0.76% to -$282.3 million in 2026.
- Business Quant data shows ALVO's Common Equity at -$282.3 million in Q1 2026, -$284.5 million in Q4 2025, and -$412.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | -282.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -282.31 Mn |
| Dec 31, 2025 | -284.49 Mn |
| Sep 30, 2025 | -412.77 Mn |
| Jun 30, 2025 | -173.33 Mn |
| Mar 31, 2025 | -412.77 Mn |
| Dec 31, 2024 | -412.77 Mn |
| Sep 30, 2024 | -343.71 Mn |
| Jun 30, 2024 | -605.92 Mn |
| Mar 31, 2024 | -658.83 Mn |
| Dec 31, 2023 | -932.49 Mn |
| Jun 30, 2023 | -478.54 Mn |
| Mar 31, 2023 | -655.77 Mn |
| Dec 31, 2022 | -564.42 Mn |
| Jun 30, 2022 | -296.22 Mn |
| Dec 31, 2021 | -135.61 Mn |
| Dec 31, 2020 | -867.24 Mn |